Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Metsera stock bidding war intensifies as Novo and Pfizer race to secure next-gen obesity drug assets amid surging market ...

Pfizer sues Metsera and Novo Nordisk for breaching merger agreement and seeks injunction to enforce deal after ...

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.

Metsera said Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer valuing the company for up to $10 billion.

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera. Novo is now offering to pay as much as $10 billion for the company, Metsera ...